This scenario presents a patient with acute decompensated heart failure (ADHF) on intravenous loop diuretic therapy. The core pathophysiological driver of the hospitalization is congestion, driven by sodium and water retention [1]. While loop diuretics like furosemide are first-line agents to relieve this congestion, their use introduces significant risks, particularly profound electrolyte disturbances. The nurse must prioritize findings that indicate a life-threatening complication over expected therapeutic responses.
The critical finding is the serum potassium level of 2.8 mEq/L accompanied by new-onset muscle weakness. This value represents severe hypokalemia. The mechanism is directly linked to the furosemide therapy; by blocking the sodium-potassium-chloride cotransporter in the thick ascending loop of Henle, furosemide massively increases the delivery of sodium to the distal nephron. This overwhelms reabsorption capacity and forces the distal tubules to exchange sodium for potassium at an accelerated rate, leading to excessive urinary potassium loss. The new muscle weakness is a direct clinical manifestation of this electrolyte deficit on neuromuscular function and is a sentinel sign of potential cardiac instability, including life-threatening ventricular arrhythmias.
The other options represent expected and desirable clinical trajectories during effective decongestive therapy. A blood pressure reduction from 140/90 to 120/80 mmHg is an anticipated hemodynamic response to reduced intravascular volume and preload. A daily weight loss of 2 pounds with decreased pedal edema is a direct indicator that the diuretic is successfully achieving its goal of mobilizing excess fluid and relieving congestion [1]. A robust urine output of 150 mL/hour signifies an adequate natriuretic response, which is the intended pharmacological effect and contrasts sharply with the inadequate response seen in diuretic resistance [1].
This question tests the principle of prioritizing care using the ABC (Airway, Breathing, Circulation) framework and the concept of "what is the most immediately life-threatening?" While all options involve assessment findings, only option 2 points directly to a high risk of cardiac dysrhythmia—a "Circulation" crisis. A potassium level below 3.0 mEq/L significantly destabilizes myocardial cell resting membrane potentials, making them hyperpolarized and less excitable, which paradoxically increases the risk for re-entrant arrhythmias. The nurse must recognize that new muscle weakness is not a minor complaint but a critical neurological sign of severe hypokalemia that warrants immediate provider notification for urgent potassium replacement to prevent cardiac arrest.
A serum potassium level of 2.8 mEq/L with new muscle weakness is a critical finding during IV furosemide therapy. This represents severe hypokalemia, which dramatically increases the risk for life-threatening ventricular arrhythmias.
Furosemide blocks the sodium-potassium-chloride cotransporter in the loop of Henle, delivering high sodium loads to the distal tubule. This forces an accelerated exchange of sodium for potassium, leading to excessive urinary potassium wasting.
Do not confuse expected therapeutic responses (weight loss, increased urine output, mild BP reduction) with this dangerous complication. New muscle weakness is a sentinel sign of impending cardiac instability and requires immediate notification of the provider for urgent potassium replacement.
학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.